A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo

Erin E. Thacker, Masaharu Nakayama, Bruce F. Smith, R. Curtis Bird, Zhanat Muminova, Theresa V. Strong, Laura Timares, Nikolay Korokhov, Ann Marie O'Neill, Tanja D. de Gruijl, Joel N. Glasgow, Kenzaburo Tani, David T. Curiel

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Targeting viral vectors encoding tumor-associated antigens to dendritic cells (DCs) in vivo is likely to enhance the effectiveness of immunotherapeutic cancer vaccines. We have previously shown that genetic modification of adenovirus (Ad) 5 to incorporate CD40 ligand (CD40L) rather than native fiber allows selective transduction and activation of DCs in vitro. Here, we examine the capacity of this targeted vector to induce immune responses to the tumor antigen CEA in a stringent in vivo canine model. CD40-targeted Ad5 transduced canine DCs via the CD40-CD40L pathway in vitro, and following vaccination of healthy dogs, CD40-targeted Ad5 induced strong anti-CEA cellular and humoral responses. These data validate the canine model for future translational studies and suggest targeting of Ad5 vectors to CD40 for in vivo delivery of tumor antigens to DCs is a feasible approach for successful cancer therapy.

Original languageEnglish
Pages (from-to)7116-7124
Number of pages9
JournalVaccine
Volume27
Issue number50
DOIs
Publication statusPublished - Nov 23 2009
Externally publishedYes

Fingerprint

Histocompatibility Antigens Class II
Adenoviridae
dendritic cells
Dendritic Cells
Canidae
Neoplasm Antigens
immune response
antigens
CD40 Ligand
neoplasms
dogs
Cancer Vaccines
Vaccination
genetic engineering
humoral immunity
Dogs
vaccination
vaccines
therapeutics
Neoplasms

Keywords

  • Adenovirus
  • Cancer immunotherapy
  • Dendritic cell
  • Dog
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. / Thacker, Erin E.; Nakayama, Masaharu; Smith, Bruce F.; Bird, R. Curtis; Muminova, Zhanat; Strong, Theresa V.; Timares, Laura; Korokhov, Nikolay; O'Neill, Ann Marie; de Gruijl, Tanja D.; Glasgow, Joel N.; Tani, Kenzaburo; Curiel, David T.

In: Vaccine, Vol. 27, No. 50, 23.11.2009, p. 7116-7124.

Research output: Contribution to journalArticle

Thacker, EE, Nakayama, M, Smith, BF, Bird, RC, Muminova, Z, Strong, TV, Timares, L, Korokhov, N, O'Neill, AM, de Gruijl, TD, Glasgow, JN, Tani, K & Curiel, DT 2009, 'A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo', Vaccine, vol. 27, no. 50, pp. 7116-7124. https://doi.org/10.1016/j.vaccine.2009.09.055
Thacker, Erin E. ; Nakayama, Masaharu ; Smith, Bruce F. ; Bird, R. Curtis ; Muminova, Zhanat ; Strong, Theresa V. ; Timares, Laura ; Korokhov, Nikolay ; O'Neill, Ann Marie ; de Gruijl, Tanja D. ; Glasgow, Joel N. ; Tani, Kenzaburo ; Curiel, David T. / A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. In: Vaccine. 2009 ; Vol. 27, No. 50. pp. 7116-7124.
@article{df27018b1c954d9a8738b6b553d63eb1,
title = "A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo",
abstract = "Targeting viral vectors encoding tumor-associated antigens to dendritic cells (DCs) in vivo is likely to enhance the effectiveness of immunotherapeutic cancer vaccines. We have previously shown that genetic modification of adenovirus (Ad) 5 to incorporate CD40 ligand (CD40L) rather than native fiber allows selective transduction and activation of DCs in vitro. Here, we examine the capacity of this targeted vector to induce immune responses to the tumor antigen CEA in a stringent in vivo canine model. CD40-targeted Ad5 transduced canine DCs via the CD40-CD40L pathway in vitro, and following vaccination of healthy dogs, CD40-targeted Ad5 induced strong anti-CEA cellular and humoral responses. These data validate the canine model for future translational studies and suggest targeting of Ad5 vectors to CD40 for in vivo delivery of tumor antigens to DCs is a feasible approach for successful cancer therapy.",
keywords = "Adenovirus, Cancer immunotherapy, Dendritic cell, Dog, Vaccine",
author = "Thacker, {Erin E.} and Masaharu Nakayama and Smith, {Bruce F.} and Bird, {R. Curtis} and Zhanat Muminova and Strong, {Theresa V.} and Laura Timares and Nikolay Korokhov and O'Neill, {Ann Marie} and {de Gruijl}, {Tanja D.} and Glasgow, {Joel N.} and Kenzaburo Tani and Curiel, {David T.}",
year = "2009",
month = "11",
day = "23",
doi = "10.1016/j.vaccine.2009.09.055",
language = "English",
volume = "27",
pages = "7116--7124",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "50",

}

TY - JOUR

T1 - A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo

AU - Thacker, Erin E.

AU - Nakayama, Masaharu

AU - Smith, Bruce F.

AU - Bird, R. Curtis

AU - Muminova, Zhanat

AU - Strong, Theresa V.

AU - Timares, Laura

AU - Korokhov, Nikolay

AU - O'Neill, Ann Marie

AU - de Gruijl, Tanja D.

AU - Glasgow, Joel N.

AU - Tani, Kenzaburo

AU - Curiel, David T.

PY - 2009/11/23

Y1 - 2009/11/23

N2 - Targeting viral vectors encoding tumor-associated antigens to dendritic cells (DCs) in vivo is likely to enhance the effectiveness of immunotherapeutic cancer vaccines. We have previously shown that genetic modification of adenovirus (Ad) 5 to incorporate CD40 ligand (CD40L) rather than native fiber allows selective transduction and activation of DCs in vitro. Here, we examine the capacity of this targeted vector to induce immune responses to the tumor antigen CEA in a stringent in vivo canine model. CD40-targeted Ad5 transduced canine DCs via the CD40-CD40L pathway in vitro, and following vaccination of healthy dogs, CD40-targeted Ad5 induced strong anti-CEA cellular and humoral responses. These data validate the canine model for future translational studies and suggest targeting of Ad5 vectors to CD40 for in vivo delivery of tumor antigens to DCs is a feasible approach for successful cancer therapy.

AB - Targeting viral vectors encoding tumor-associated antigens to dendritic cells (DCs) in vivo is likely to enhance the effectiveness of immunotherapeutic cancer vaccines. We have previously shown that genetic modification of adenovirus (Ad) 5 to incorporate CD40 ligand (CD40L) rather than native fiber allows selective transduction and activation of DCs in vitro. Here, we examine the capacity of this targeted vector to induce immune responses to the tumor antigen CEA in a stringent in vivo canine model. CD40-targeted Ad5 transduced canine DCs via the CD40-CD40L pathway in vitro, and following vaccination of healthy dogs, CD40-targeted Ad5 induced strong anti-CEA cellular and humoral responses. These data validate the canine model for future translational studies and suggest targeting of Ad5 vectors to CD40 for in vivo delivery of tumor antigens to DCs is a feasible approach for successful cancer therapy.

KW - Adenovirus

KW - Cancer immunotherapy

KW - Dendritic cell

KW - Dog

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=70350568201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350568201&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.09.055

DO - 10.1016/j.vaccine.2009.09.055

M3 - Article

VL - 27

SP - 7116

EP - 7124

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 50

ER -